Risk of Subsequent Solid Tumors After Non-Hodgkin's Lymphoma: Effect of Diagnostic Age and Time Since Diagnosis

Hemminki, Kari; Lenner, Per; Sundquist, Jan; Bermejo, Justo Lorenzo

doi:10.1200/jco.2007.14.6068

Cited by 62 publications

(53 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found a borderline increased risk of bladder cancer (SIR ¼ 1.61) in women affected by non-Hodgkin lymphoma, the SIR was 1.95 for male patients. These estimates were slightly higher than the overall SIR of 1.50 found in an international study, which included part of the Swedish cohort (Brennan et al, 2005;Hemminki et al, 2008). International studies take benefit from a large number of patients, but standard registration and homogeneity in treatment and exposure were important plus factors of this study.…”

Section: Discussioncontrasting

confidence: 44%

Bladder cancer in cancer patients: population-based estimates from a large Swedish study

Bermejo

Sundquist²,

Hemminki

2009

Br J Cancer

View full text Add to dashboard Cite

BACKGROUND: This study quantified the risk of urinary bladder neoplasms in cancer patients taking into account the age at first diagnosis, the gender of the patients and the lead time between diagnoses. METHODS: We used standardised incidence ratios (SIRs) to compare the incidence of bladder tumours in 967 767 cancer patients with the incidence rate in the general Swedish population. A total of 3324 male and 1560 female patients developed bladder tumours at least 1 year after first cancer diagnosis. RESULTS: After bladder and renal pelvis cancers, the SIRs of bladder neoplasms were higher in female than in male patients. Men affected by lung, stomach and larynx tumours belonged to the population at high risk for bladder cancer. Treatment of breast, ovarian and cervical cancers seems to contribute to the subsequent development of bladder neoplasms. Long latencies (16 -25 years) were observed after testicular, cervical and endometrial cancers. Detection bias had an important role after prostate cancer. Chemotherapy with cyclophosphamide and cisplatin, and also radiotherapy, seem to increase the risk of subsequent neoplasms in the bladder. CONCLUSIONS: These population-based results may help urologists to assess the risk of bladder neoplasms in cancer survivors. Our data should guide ongoing studies that investigate the effectiveness of bladder cancer screening in cancer patients.

show abstract

Section: Discussioncontrasting

confidence: 44%

Bladder cancer in cancer patients: population-based estimates from a large Swedish study

Bermejo

Sundquist²,

Hemminki

2009

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…[139][140][141] Among 104,760 one-year survivors of cervical cancer, patients heavily treated with RT were at increased risk for second cancers at sites in proximity to the cervix beyond 40 years of followup. The 40-year cumulative risk for any second cancer was higher among women diagnosed before 50 years of age than among those diagnosed after 50 years of age (22.2% and 16.4%, respectively).…”

Section: Survivorship Issuesmentioning

confidence: 99%

“…140 In an analysis of 28,131 patients from the Swedish Cancer Registry, the risk of developing subsequent solid tumors after NHL during the first decade was higher among patients diagnosed between 20 and 39 years of age compared with those who were 40 years of age or older at diagnosis. 141 In the SEER database analysis of 89,515 melanoma survivors, patients diagnosed at younger than 30 years had the highest risk of developing secondary cancers (breast, prostate, and NHL being the most common cancers) at more than 20 years after initial diagnosis.…”

Section: Survivorship Issuesmentioning

confidence: 99%

Adolescent and Young Adult Oncology

Coccia¹,

Altman²,

Bhatia

et al. 2012

J Natl Compr Canc Netw

185

132

View full text Add to dashboard Cite

“…Recently large epidemiological studies on nervous system cancer have been carried out but a few environmental risk factors have consistently been identified (Bondy et al, 2008). Therapeutic and low-level irradiation, hereditary syndromes and family history remain as the established risk factors of nervous system tumours (Stewart and Kleihues, 2003;Hijiya et al, 2007;Maule et al, 2007;Hemminki et al, 2008a). Less than 3% of patients with nervous system tumours have a first-degree family member diagnosed by these neoplasms (Hemminki et al, 2008b).…”

mentioning

confidence: 99%

Familial risks in nervous system tumours: joint Nordic study

et al. 2010

View full text Add to dashboard Cite

BACKGROUND: Familial nervous system cancers are rare and limited data on familial aspects are available particularly on site-specific tumours. METHODS: Data from five Nordic countries were used to analyse familial risks of nervous system tumours. Standardised incidence ratios (SIRs) were calculated for offspring of affected relatives compared with offspring of non-affected relatives. RESULTS: The total number of patients with nervous system tumour was 63 307, of whom 32 347 belonged to the offspring generation. Of 851 familial patients (2.6%) in the offspring generation, 42 (4.7%) belonged to the families of a parent and at least two siblings affected. The SIR of brain tumours was 1.7 in offspring of affected parents; it was 2.0 in siblings and 9.4 in families with a parent and sibling affected. For spinal tumours, the SIRs were much higher for offspring of early onset tumours, 14.0 for offspring of affected parents and 22.7 for siblings. The SIRs for peripheral nerve tumours were 16.3 in offspring of affected parents, 27.7 in siblings and 943.9 in multiplex families. CONCLUSION: The results of this population-based study on medically diagnosed tumours show site-, proband-and age-specific risks for familial tumours, with implications for clinical genetic counselling and identification of the underlying genes.

show abstract

Risk of Subsequent Solid Tumors After Non-Hodgkin's Lymphoma: Effect of Diagnostic Age and Time Since Diagnosis

Abstract: These data indicate that age at treatment determines both the magnitude of the initial relative risk and the time-dependent modulation of the response. Therapy-related damage persists at least 30 years and its toll of solid tumors is largest 21 to 30 years after diagnosis.

Cited by 62 publications

References 28 publications

Bladder cancer in cancer patients: population-based estimates from a large Swedish study

Bladder cancer in cancer patients: population-based estimates from a large Swedish study

Adolescent and Young Adult Oncology

Familial risks in nervous system tumours: joint Nordic study

Contact Info

Product

Resources

About